Amendment to Employment Agreement, effective as of November 27, 2023, by and between the Company and Patrick Yeramian
Exhibit 10.13
2nd AMENDMENT TO EMPLOYMENT AGREEMENT
This 2nd Amendment to Employment Agreement (“Amendment”) is made between Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Patrick Yeramian, M.D. (“Executive”) and is effective as of November 27, 2023 (the “Effective Date”).
WHEREAS, the Company and Executive are parties to that certain Employment Agreement, effective January 11, 2022 (the “Employment Agreement”), as amended in that certain Amendment to Employment Agreement effective December 1, 2022 (the “Amendment”); and
WHEREAS, the parties wish to amend the Employment Agreement to reflect that Executive will no longer be Chief Medical Officer but will have the title Strategic Advisor for the remainder of his employment; and
WHEREAS, all other terms and conditions of the Employment Agreement, inclusive of the Amendment, will remain effective.
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
(b) Position and Duties. The Executive shall serve as Strategic Advisor to the Company and shall have such powers and duties as may from time to time be prescribed by the Co-Chief Executive Officers (individually and collectively, the “CEO”) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company; provided, however, that Executive’s full working time and efforts shall be twenty (20) hours per week. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.
IN WITNESS WHEREOF, the parties have executive this Amendment effective on the Effective Date.
| AMYLYX PHARMACEUTICALS, INC. | ||
| By: | /s/ Justin Klee | |
| Justin Klee | ||
| Co-Chief Executive Officer | ||
|
|
|
|
|
| EXECUTIVE | |
|
|
|
|
|
| By: | /s/ Patrick Yeramian |
|
|
| Patrick Yeramian, M.D. |
|
|
|
|